ARK Genomic Revolution ETF Gains 1% on Personalis Securing Lung Cancer Test Coverage
ARK Genomic Revolution ETF rose 1.01% after Personalis, representing 6.35% of its assets, received Medicare coverage for its NeXT Personal molecular residual disease test for Stage I–III non–small cell lung cancer. Personalis shares climbed nearly 15%, boosting the ETF’s exposure to genomic diagnostics and attracting inflows.
1. Personalis Secures Medicare Coverage
Personalis’s NeXT Personal MRD test for monitoring recurrence in Stage I–III non–small cell lung cancer will now be covered by Medicare, expanding patient access for a test that tracks up to 1,800 mutations following TRACERx validation.
2. ARKG Market Reaction
ARK Genomic Revolution ETF shares rose 1.01% as Personalis, a 6.35% holding, climbed 14.9% on the coverage news, underscoring the catalyst’s immediate impact on fund performance.
3. Fund Inflows and Outlook
Enhanced reimbursement could drive higher demand for Personalis and attract fresh capital into the ETF, boosting net inflows and amplifying exposure to advanced genomic diagnostics.